

Content available at: <https://www.ipinnovative.com/open-access-journals>

Indian Journal of Obstetrics and Gynecology Research

Journal homepage: [www.ijogr.org](http://www.ijogr.org)

## Original Research Article

# Assessment of risk of malignancy index scoring and histopathological correlation in the diagnosis and management of adnexal mass

Uvajanani S S<sup>1,\*</sup>, Maharajan S<sup>1</sup>, T V Indirani<sup>1</sup><sup>1</sup>Dept. of Obstetrics and Gynaecology, Madurai Medical College, Madurai, Tamil Nadu, India

## ARTICLE INFO

## Article history:

Received 09-11-2022

Accepted 27-02-2023

Available online 18-05-2023

## Keywords:

RMI

Adnexal mass

CA 125

## ABSTRACT

**Introduction:** Pathologies of adnexal masses are commonly benign. The malignant lesions of adnexa carries a very low five-year survival rate, and hence the early recognition need to be done. There is no single gold standard investigation for the diagnosis of the malignancy of the adnexa. Risk of Malignancy Index (RMI) scoring system, combines the Serum CA 125(U/ML), Ultrasound score (U) and the menopausal status(M).

**Objectives:** To assess the efficiency of Risk of Malignancy Index-3 (RMI-3) scoring system in discriminating benign and malignant adnexal mass, for early detection and management of malignant ovarian mass.

**Materials and Methods:** This is a prospective, observational study, among 50 female patients above the age of 25 years, diagnosed with adnexal mass under the Department of obstetrics and gynaecology, Government Rajaji Hospital, affiliated to Madurai Medical College, Madurai.

All the study participants were subjected to detailed history taking, thorough clinical examination, ultrasonogram of abdomen and pelvis, and markers such as CA 125. Risk of Malignancy Index was calculated and correlated with the histopathological (HPE) findings of the excised tumours.

**Results:** When the cut off of RMI score for predicting malignancy is 149.2 which had a sensitivity of 79.2%, specificity of 92.3%, positive predictive value of 90.47%, negative predictive value of 82.78% and a diagnostic accuracy of 86.01%.

**Conclusion:** Risk of Malignancy Index score is a simple tool, with a good diagnostic accuracy, hence it can be used as good screening tool for identification of the malignant lesions from the adnexal mass.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

## 1. Introduction

Adnexa is the area next to the uterus containing ligaments, vessels, fallopian tubes, ovaries.<sup>1</sup> Adnexal masses are the growth near the uterus, usually in the ovary or fallopian tube. Adnexal masses includes commonly the ovarian cysts, ectopic (tubal) pregnancies, and tumours (benign or malignant).<sup>2</sup>

Adnexal masses are the fourth most common gynaecological cause for hospitalisation and 90% have

benign characteristics.


Risk of malignancy found to be 13% in premenopausal women and 45% in postmenopausal women.<sup>3,4</sup> Adnexal masses represent a spectrum of conditions from gynaecological and non-gynaecological sources. They may be benign or malignant. The initial detection and evaluation of an adnexal mass requires a high index of suspicion. Appropriate lab and radiographic studies are required.<sup>5</sup>

The most common symptoms reported are abdominal pain, abdomen distension, bloating, urinary urgency, incontinence, weight loss. This requires further evaluation


\* Corresponding author.

E-mail address: [uvatheni@gmail.com](mailto:uvatheni@gmail.com) (Uvajanani S S).

if it persists for more than 2 weeks or failure to respond to appropriate therapy.



**Fig. 1:** Anatomy of the adnexa. Citation: “Gross Anatomy of the Female Reproductive System.”. Lecturio., .Web. 5 Dec. 2022 (https://app.lecturio.com/#/article/3847)



**Fig. 2:** Posterior view of the adnexa and the related structures. Citation: Gross Anatomy of the Female Reproductive System.” Lecturio., .Web. 5 Dec. 2022. (https://app.lecturio.com/#/article/3847)

The risk increases with age, with greater risks after menopause. Most of the patients present in an advanced stage for which 5 year survival rate remains very low. Hence, it is important to discriminate between benign and malignant nature of the adnexal mass at an earlier stage.<sup>6,7</sup>

Non-malignant adnexal masses can be managed, however prepubertal and postmenopausal women with adnexal masses should be evaluated earlier for a better prognosis. Hence, the goal is to differentiate between benign and malignant masses. CA-125 is a used as a screening tool for ovarian malignancy, elevated in almost 80% of ovarian cancer.<sup>8</sup>

CA-125 is a non-specific marker for ovarian malignancy, also elevated in other malignancies (endometrial cancer, germ cell tumour, cervical cancer, breast cancer, colon cancer, pancreatic cancer), pregnancy, pelvic inflammatory diseases, adenomyosis etc., It is found to be elevated in 1% of normal females. CA-125 levels less than 35 are considered to be within the normal limit.<sup>8</sup>

The sensitivity of CA 125 value is low. Not all malignant ovarian cancer was associated with elevated CA 125. It

is useful for predicting the recurrence of ovarian tumour at earliest and in predicting the treatment effectiveness of patients undergoing chemotherapy for ovarian cancer.

Risk of malignancy index (RMI) is a parameter which is simple, easy to use, practical and highly sensitive, and more specific.

Risk of Malignancy Index is calculated from the three parameters by the following formula, "RMI=U \* M \*CA 125"

Risk of Malignancy Index (RMI) scoring system, combines the Serum CA 125(U/ML), Ultrasound score (U) and the menopausal status (M).

**Table 1:**

Parameters	RMI 1	RMI 2	RMI 3	RMI 4
USG Criteria				
No feature	0	1	1	1
1 Feature	1	1	1	1
>2 Feature	3	4	3	4
Premenopausal	1	1	1	1
Postmenopausal	3	4	3	4
CA125	-	-	-	-
Tumour size<7cm	-	-	-	1
Tumour size>7cm	-	-	-	2

## 2. Aim and Objectives

To assess the efficiency of Risk of Malignancy Index-3 (RMI-3) scoring system in discriminating benign and malignant adnexal mass, and to compare the RMI 1 and RMI 4 Scoring for early detection and management of malignant ovarian mass.

### 2.1. Primary objectives

To assess the efficiency of Risk of Malignancy Index-3 (RMI-3) scoring system in discriminating benign and malignant adnexal mass compared to the histopathological results.

### 2.2. Secondary objectives

To study the usefulness of the RMI-3 Scoring for early detection and management of malignant ovarian mass.

Currently, the risk of malignancy index is a scoring system developed to improve the diagnostic accuracy of malignant ovarian tumour. Risk of Malignancy Index is based on Ultrasound score, Menopausal status and CA 125 level as follows, RMI score = Ultrasound score x Menopausal score x CA - 125 concentration.

#### USG score

Features of malignancy on ultrasound comprise of,

1. Irregular solid or multi-loculated cystic mass
2. Solid components on cyst wall

3. High-Doppler flow in solid components
4. Ascites, peritoneal-nodules, or other evidence of metastases

0 = no features of malignancy on ultrasound

1 = one feature of malignancy on ultrasound

3 = two or more features of malignancy on ultrasound

M score

1 = premenopausal

3 = postmenopausal

#### **Interpretation of RMI scores**

<25 - Low Risk - Repeat clinical assessment, with MRI if ultrasound features are borderline.

25 to 200 - Moderate or Intermediate Risk - MRI recommended.

>200 - High Risk - Referral to specialist gynaecological cancer service, and staging CT. [18,37]

### **3. Materials and Methods**

#### *3.1. Study subjects*

50 female patients above the age of 25 years, diagnosed with adnexal mass under the department of obstetrics and gynaecology, Government Rajaji Hospital, affiliated to Madurai Medical College, Madurai.

#### *3.2. Study design*

Prospective, observational study.

#### *3.3. Study period*

Data collection –1 year (2020 December to 2022 January).

#### *3.4. Study setting*

Department of obstetrics and gynaecology, Government Rajaji Hospital, affiliated to Madurai Medical College, Madurai.

#### *3.5. Sampling procedure*

Convenient sampling.

#### *3.6. Inclusion criteria*

1. Female patients age above 25 years.
2. Both premenopausal and post-menopausal women.
3. All symptomatic individual diagnosed to have adnexal mass.

#### *3.7. Exclusion criteria*

1. Age less than 25
2. Pregnant women
3. Patient on peritoneal dialysis
4. Patient who are not willing to give informed consent

5. Asymptomatic individuals.

#### *3.8. Sample size*

The total sample size for the study is 50.

#### *3.9. Ethical consideration*

Institutional Ethical Committee approval, from Madurai Medical College, Madurai, was obtained before the start of the study. Informed written consent was obtained.

#### *3.10. Study procedure*

After obtaining the IEC approval, the patients who meet the inclusion criteria, were included in the study. Informed and written consent was obtained from each of the study participants. All the study participants were subjected to detailed history taking, thorough clinical examination, ultrasonogram of abdomen and pelvis, and markers such as CA 125. After pre-op evaluation, patients were taken up for surgery. Other investigations, such as complete blood count, Random blood sugar, renal function test, liver function test and histopathology were done.

Menopausal statuses were assessed. M=1 if premenopausal M=3 if postmenopausal.

Serum CA-125 and Ultrasound examination were performed.

A total ultrasound score U was calculated for each patients after assessing all 5 parameters. Ultrasound score was assigned U=1 if 0 or 1 criteria fulfilled and ultrasound score U=3 if 2 or more criteria fulfilled. RMI was calculated for all the patients.

Preoperative assessment was done for all patients. After a thorough preoperative evaluation and aesthetic fitness an informed written consent was obtained and the patients were taken up for laparotomy. After surgery, histopathological (HPE) findings of the excised tumours were analysed in order to determine the final diagnosis. Post-operative follow up were done at 3/6/12 month.

#### *3.11. Budget*

Self. (No added investigation or intervention)

#### *3.12. Statistical methods*

##### *3.12.1. Descriptive statistics*

1. Numerical variables like Age, CA-125 values, Blood investigation values etc, are represented in mean, SD, median, and mode. Histograms are used wherever necessary.
2. Categorical variables like benign/malignant nature of lesion on histopathology, RMI scoring, etc., are represented in frequencies and percentages. Pie-charts and bar diagrams are used as appropriate.

3. Data was entered in MS excel sheet and analysed using SPSS software version 16.

3.13. Inferential statistics

1. Prediction of benign/malignant nature of the lesion by RMI scoring is compared with the presence of benign/malignant nature of lesion by histopathology, by the sensitivity, specificity, positive predictive value and negative predictive values. ROC curves were plot and diagnostic accuracy were represented.
2. P-values less than 0.05 were considered statistically significant.

4. Results

Results of the study, on efficiency of Risk of Malignancy Index (RMI) scoring system in discriminating benign and malignant adnexal mass compared to the histopathological results, is discussed.

**Table 2:** The mean age (years) among the subjects was 48.76 (± 13.06) years ranging from 23 to 72 years.

Age (years)	
Mean	48.76
Median	50
Std. Deviation	13.06
Range	49
Minimum	23
Maximum	72

**Table 3:** Among the subjects, 14 (28%) had <= 40 years followed by 14 (28%) had <= 40 years and least 10 (20%) had > 60 years

Age group	Frequency	Percent
<= 40 years	14	28.00
41 - 50 years	12	24.00
51 - 60 years	14	28.00
> 60 years	10	20.00
Total	50	100.00

**Table 4:** Menopausal score-among the subjects, 25 (50%) had score 1 and 25 (50%) had score 3

Menopausal Score	Frequency	Percent
1	25	50.00
3	25	50.00
Total	50	100.00

5. Discussion

This is a prospective, observational study, among 50 female patients above the age of 25 years, diagnosed with adnexal mass under the department of obstetrics and gynaecology, Government Rajaji Hospital, affiliated to Madurai Medical

**Table 5:** USG score-among the subjects, 27 (54%) had score 3 and 23 (46%) had score 1

USG score	Frequency	Percent
1	23	46.00
3	27	54.00
Total	50	100.00

**Table 6:** CA 125- The mean CA-125 level among the subjects was 77.81 (± 95.44) ranging from 4.5 to 350 U/ml

CA-125 level (U/ml)	
Mean	77.81
Median	32
Std. Deviation	95.44
Range	345.5
Minimum	4.5
Maximum	350

**Table 7:** RMI Score- The mean RMI score among the subjects was 487.43 (± 793.37) ranging from 4.5 to 315

RMI score	
Mean	487.43
Median	117.5
Std. Deviation	793.37
Range	3145.5
Minimum	4.5
Maximum	3150

**Table 8:** Among the subjects, 14 (28%) had Serous Cystadenoma Carcinoma followed by 7 (14%) had Benign Serous Cystadenoma and least 1 (2%) had Clearcell Tumour

Histopathological diagnosis	Frequency	Percent
Benign Serous Cystadenoma	7	14.00
Clear cell Tumour	1	2.00
Dermoid Cyst	3	6.00
Endometrioid Adeno Carcinoma	3	6.00
Endometrioma	1	2.00
Fibroma	1	2.00
Fibrothecoma	2	4.00
Follicular Cyst	4	8.00
Granulosa Cell Tumour	1	2.00
Mature Cystic Teratoma	2	4.00
Mucinous Cystadenoma	5	10.00
Mucinous Cystadenoma Carcinoma	4	8.00
Serous Cystadenoma	2	4.00
Serous Cystadenoma Carcinoma	14	28.00
Total	50	100.00

**Table 9:** Among the subjects, 26 (52%) had Benign and 24 (48%) had Malignant tumours

Tumour type	Frequency	Percent
Malignant	24	48.00
Benign	26	52.00
<b>Total</b>	<b>50</b>	<b>100.00</b>

**Table 10:** Comparison of age group with the tumour type

Age group	Tumour type		Total	Fisher exact p value
	Malignant	Benign		
<= 40 years	3 (21.42%)	11 (78.57%)	14 (100%)	0.01
41 - 50 years	7 (58.33%)	5 (41.66%)	12 (100%)	
51 - 60 years	7 (50%)	7 (50%)	14 (100%)	
> 60 years	7 (70%)	3 (30%)	10 (100%)	
<b>Total</b>	<b>24 (48%)</b>	<b>26 (52%)</b>	<b>50 (100%)</b>	

**Table 11:** The mean RMI score among Malignant was 953.52 (± 949.17) which is higher by 896.33 and statistically significant compared to 57.19 (± 61.56) in Benign

	Tumour type	N	Mean	Std. dev.	Mean diff.	p value by 't' test
RMI score	Malignant	24	953.52	949.17	896.330	0.001
	Benign	26	57.19	61.56		

**Table 12:**

Test Result Variable(s)	Cut off	Sensitivity	Specificity	PPV	NPV	Accuracy
RMI score	241.50	75.0%	100.00%	100.00%	81.25%	88%
	149.20	79.20%	92.30%	90.47%	82.78%	86.01%
	111.50	83.30%	76.90%	76.90%	83.30%	79.97%

College, Madurai. All the study participants were subjected to detailed history taking, thorough clinical examination, ultrasonogram of abdomen and pelvis, and markers such as CA 125.

Risk of Malignancy Index was calculated and correlated with the histopathological (HPE) findings of the excised tumours.

The main objective of the study is to assess the efficiency of Risk of Malignancy Index-3 (RMI-3) scoring system in

discriminating benign and malignant adnexal mass, for early detection and management of malignant ovarian mass.

The mean RMI score observed among the Malignant lesions was 953.52 (± 949.17) which is higher by 896.33 and statistically significant compared to 57.19 (± 61.56) in Benign lesions.

## 6. Results

The study population comprise of 50 female patients above the age of 25 years, diagnosed with adnexal mass under the Department of obstetrics and gynaecology, Government Rajaji Hospital, affiliated to Madurai Medical College.

### 6.1. Risk of malignancy parameters and diagnosis

1. **Menopausal Score:** Among the subjects, 25 (50%) had score 1 and 25 (50%) had score 3.
2. **USG score:** Among the subjects, 27 (54%) had score 3 and 23 (46%) had score 1.
3. **CA-125 level:** The mean CA-125 level among the subjects was 77.81 ( $\pm 95.44$ ) ranging from 4.5 to 350 U/ml.
4. **RMI score:** The mean RMI score among the subjects was 487.43 ( $\pm 793.37$ ) ranging from 4.5 to 3150.
5. **Histopathological diagnosis:** Among the subjects, 26 (52%) had Benign and 24 (48%) had Malignant tumours. Among the subjects, 14 (28%) had Serous Cystadenoma Carcinoma followed by 7 (14%) had Benign Serous Cystadenoma and least 1 (2%) had Clear cell Tumour.

### 6.2. Comparison of RMI score and its parameters with the tumour type

1. **Comparison of menopausal Score with the tumour type:** 32% of the subjects with score 1 were malignant type which is lower compared to subjects with score 3 of whom 64% were malignant type and the difference was statistically significant ( $p < 0.05$ ).
2. **Comparison of USG score with the tumour type:** 17.39% of the subjects with score 1 were malignant type which is lower compared to subjects with score 3 of whom 74.07% were malignant type and the difference was statistically significant ( $p < 0.05$ ).
3. **RMI score with tumour type:** The mean RMI score among Malignant lesions, which was 953.52 ( $\pm 949.17$ ) which is higher by 896.33 and statistically significant compared to 57.19 ( $\pm 61.56$ ) in Benign lesions.

### 6.3. Accuracy of predicting malignancy using RMI score

The area under the curve for RMI score in predicting malignancy is 0.905(0.819 - 0.991).

When the cut off of RMI score for predicting malignancy is 241.5 which had a sensitivity of 75%, specificity of 100%, positive predictive value of 100%, negative predictive value of 81.25% and a diagnostic accuracy of 88%.

When the cut off of RMI score for predicting malignancy is 111.5 which had a sensitivity of 83.3%, specificity

of 76.9%, positive predictive value of 76.9%, negative predictive value of 83.3% and a diagnostic accuracy of 79.97%.

When the cut off of RMI score for predicting malignancy is 149.2 which had a sensitivity of 79.2%, specificity of 92.3%, positive predictive value of 90.47%, negative predictive value of 82.78% and a diagnostic accuracy of 86.01%.

By using Binomial regression, for each unit increase in RMI score, the odds of getting malignancy increases by 1.01 times which is statistically significant.

## 7. Conclusion

The mean RMI score among Malignant lesions, which was 953.52 ( $\pm 949.17$ ) significantly higher, compared to 57.19 ( $\pm 61.56$ ) in Benign lesions. The area under the ROC curve for RMI score in predicting malignancy is 0.905 (0.819-0.991). When the cut off of RMI score for predicting malignancy is 149.2 which had a sensitivity of 79.2%, specificity of 92.3%, positive predictive value of 90.47%, negative predictive value of 82.78% and a diagnostic accuracy of 86.01%.

Risk of Malignancy Index score is a simple tool, with a good diagnostic accuracy, hence it can be used as good screening tool for identification of the malignant lesions from the adnexal mass.

## 8. Source of Funding

None declared.


## 9. Conflict of Interest

None declared.

## References

1. Craig ME, Sudanagunta S, Billow M. Anatomy, Abdomen and Pelvis, Broad Ligaments. Treasure Island (FL): StatPearls Publishing; 2021. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK499943/>.
2. Definition of adnexal mass - NCI Dictionary of Cancer Terms - NCI [Internet]. [Cited 2022 Oct 10]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adnexal-mass>.
3. Biggs WS, Marks ST. Diagnosis and management of adnexal masses. *Am Fam Physician*. 2016;93(8):676–81.
4. Rockall A, Forstner R. Adnexal Diseases. In: Diseases of the Abdomen and Pelvis 2018-2021: Diagnostic Imaging - IDKD Book [Internet]. Cham (CH): Springer; 2018. p. 75–84.
5. Levine D, Brown DL, Andreotti RF, Benacerraf B, Benson CB, Brewster WR, et al. Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement. *Radiology*. 2010;256(3):943–54.
6. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. *Int J Womens Health*. 2019;11:287–99.
7. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. *Cancer Biol Med*. 2017;14(1):9–32.
8. Scholler N, Urban N. CA125 in Ovarian Cancer. *Biomark Med*. 2007;1(4):513–23.

## Author biography

Uvajanani S S, MS OG  <https://orcid.org/0000-0003-1124-8581>

Maharajan S, MD

T V Indirani, Professor

**Cite this article:** Uvajanani S S, Maharajan S, Indirani TV. Assessment of risk of malignancy index scoring and histopathological correlation in the diagnosis and management of adnexal mass. *Indian J Obstet Gynecol Res* 2023;10(2):119-125.